SCM Lifescience Co., Ltd. (KOSDAQ:298060)

Market Cap	28.24B
Revenue (ttm)	889.44M
Net Income (ttm)	-15.65B
Shares Out	20.47M
EPS (ttm)	-763.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	272,017
Average Volume	148,357
Open	1,313.00
Previous Close	1,313.00
Day's Range	1,312.00 - 1,400.00
52-Week Range	1,240.00 - 4,300.00
Beta	1.12
RSI	41.97
Earnings Date	n/a

About SCM Lifescience

SCM Lifescience Co., Ltd. operates in the stem cell therapy, CMO, contract research and consulting, and cosmetic businesses. The company develops allogeneic stem cell therapeutics using its stem cell isolation technology and conducting clinical trials for immunological conditions and tissue regeneration; provides CMO services for manufacturing control and quality assurance tests; and offers adult stem cell research services. It also provides skin cell science services. The company was founded in 2014 and is headquartered in Incheon, South Korea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 298060

Financial Performance

In 2023, SCM Lifescience's revenue was 695.70 million, an increase of 75.69% compared to the previous year's 395.98 million. Losses were -23.96 billion, 4.50% more than in 2022.